How do you manage a patient with metastatic NSCLC whose initial mutation testing was limited or results are no longer available?

If I see a patient with new metastatic NSCLC with limited/no next-generation sequencing (NGS) testing, I will attempt to initiate testing in some way while formulating a treatment plan. Specifically, I will either attempt to do tumor based NGS if feasible and timely (goal for getting results back in...

I agree this is a great question and I agree with what had already been said- the only point I would add is the importance of recognizing what it means for mutation testing to be 'insufficient'.

I believe this is not only in cases where a few genes were tested, but also in cases where liquid biopsy...

Many commercial test vendors generally host their own online "portal" for results with a search function thus it is helpful to create an account, some of which can also be enabled to permit administrative personnel to centrally manage all incoming results for a group practice. Thus, if the ordering ...

This is a great question and comes up often. I tend to do liquid biopsy right then and there and order the tissue re-biopsy if there is a lesion that would be amenable for a biopsy. If we are lucky and there are positive liquid biopsy results, I might cancel the tissue biopsy but I do think that eve...